Filed by Mylan N.V.
Pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12
under the Securities Exchange Act of 1934
Subject Company: Mylan N.V.
Commission File No.: 333-199861
The following communication is being filed in connection with the proposed business combination between Mylan N.V. and Upjohn Inc., Pfizer Inc.s off-patent branded and generic established medicines business.
The following is the transcript of the Viatris
brand reveal video presented at the 38th Annual J.P. Morgan Healthcare Conference held on January 15, 2020 and made available for replay beginning on January 15, 2020 on https://www.championforglobalhealth.com/en/materials/videos.
Our world needs us to come together like never before.
To make
good on the belief that the path to better health is achieved through greater access, making it possible to live life better today and tomorrow.
Our
world needs us to lead the way by innovating around the clock and around the globe, so that the quality medicines we make, supply and deliver, create a path of value for people everywhere.
Our world needs us to partner with patients, physicians, nurses, pharmacists, and each other to untap opportunities and deliver a more hopeful and sustainable
healthcare journey that empowers people around the world to live healthier at every stage of life.
We are Viatris.
Forward-Looking Statements
This communication contains
forward-looking statements. Such forward-looking statements may include, without limitation, statements about the proposed combination of Upjohn Inc. (Newco) and Mylan N.V. (Mylan), which will immediately follow
the proposed separation of the Upjohn business (the Upjohn Business) from Pfizer Inc. (Pfizer) (the proposed transaction), the expected timetable for completing the proposed transaction, the benefits and synergies
of the proposed transaction, future opportunities for the combined company and products and any other statements regarding Pfizers, Mylans, the Upjohn Businesss or the combined companys future operations, financial or
operating results, capital allocation, dividend policy, debt ratio, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, competitions, and other expectations and targets for future
periods. Forward-looking statements may often be identified by the use of words such as will, may, could, should, would, project, believe, anticipate,
expect, plan, estimate, forecast, potential, pipeline, intend, continue, target, seek and variations of these words or comparable
words. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such
differences include, but are not limited to: the parties ability to meet expectations regarding the timing, completion and accounting and